Esophageal Cancer PDX Models

Esophageal cancer is the 6th most common cause of cancer-related deaths which drives a need for a better understanding of the underlying mechanisms behind the disease through preclinical models. Patient-derived xenograft (PDX) models provide a true representation of human heterogeneity and can be used to better understand these mechanisms in relation to the development of new therapies. CrownBio has a large selection of well-characterized esophageal cancer PDX models, including models with EGFR amplification. More

PDX offer the most translational preclinical model for efficacy screening in cancer drug development. Derived directly from patient tumors and never adapted to grow in vitro, PDX models reflect the heterogeneity and diversity of the human patient population. PDX give you an accurate, predictive model of how your treatment will perform, well before entering into expensive clinical trials. CrownBio’s HuPrime® PDX models are well characterized for pathology, growth characteristics, and are also genetically/genomically annotated for gene expression, gene copy number, mutations, and fusions.
MODEL NUMBER CANCER SUBTYPE # per page
ES0026 ESCCCLICK TO VIEW
ES0042 ESCCCLICK TO VIEW
ES0110 ESCCCLICK TO VIEW
ES0136 ESCCCLICK TO VIEW
ES0141 ESCCCLICK TO VIEW
ES0147 ESCCCLICK TO VIEW
ES0148 ESCCCLICK TO VIEW
ES0159 ESCCCLICK TO VIEW
ES0168 ESCCCLICK TO VIEW
ES0172 ESCCCLICK TO VIEW
ES0176 ESCCCLICK TO VIEW
ES0178 ESCCCLICK TO VIEW
ES0181 CLICK TO VIEW
ES0183 EACCLICK TO VIEW
ES0184 ESCCCLICK TO VIEW
ES0189 ESCCCLICK TO VIEW
ES0190 ESCCCLICK TO VIEW
ES0191 ESCCCLICK TO VIEW
ES0195 ESCCCLICK TO VIEW
ES0199 ESCCCLICK TO VIEW